Eli Lilly And Co (LLY) Issues FY19 Earnings Guidance

Eli Lilly And Co (NYSE:LLY) updated its FY19 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $5.60-5.70 for the period, compared to the Thomson Reuters consensus estimate of $5.61. The company issued revenue guidance of $22-22.5 billion, compared to the consensus revenue estimate of $22.22 billion.Eli Lilly And Co also updated its FY 2019 guidance to $5.60-5.70 EPS.

A number of research analysts have issued reports on LLY shares. Barclays reiterated a buy rating and issued a $130.00 price target on shares of Eli Lilly And Co in a research report on Sunday, January 20th. JPMorgan Chase & Co. started coverage on shares of Eli Lilly And Co in a research report on Tuesday, March 12th. They issued an overweight rating and a $140.00 price target on the stock. Guggenheim cut Eli Lilly And Co from a buy rating to a neutral rating and set a $125.84 target price for the company. in a research note on Thursday, April 11th. Zacks Investment Research raised Eli Lilly And Co from a sell rating to a hold rating in a research note on Tuesday, March 19th. Finally, UBS Group started coverage on Eli Lilly And Co in a research note on Wednesday, January 23rd. They set a buy rating and a $131.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $118.83.

Shares of NYSE:LLY traded up $0.09 during midday trading on Wednesday, hitting $115.03. The stock had a trading volume of 48,605 shares, compared to its average volume of 5,521,171. Eli Lilly And Co has a 12 month low of $80.96 and a 12 month high of $132.13. The stock has a market capitalization of $111.03 billion, a PE ratio of 20.68, a P/E/G ratio of 2.03 and a beta of 0.27. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.12 billion. During the same quarter last year, the firm posted $1.31 EPS. The company’s quarterly revenue was up 2.6% on a year-over-year basis. On average, equities analysts predict that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Friday, May 17th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a yield of 2.24%. The ex-dividend date is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is 46.49%.

In other news, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly And Co stock in a transaction on Friday, February 15th. The stock was sold at an average price of $121.00, for a total transaction of $3,025,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Aarti S. Shah sold 1,800 shares of Eli Lilly And Co stock in a transaction on Friday, April 5th. The stock was sold at an average price of $125.85, for a total value of $226,530.00. Following the sale, the senior vice president now directly owns 18,425 shares of the company’s stock, valued at approximately $2,318,786.25. The disclosure for this sale can be found here. Insiders have sold a total of 870,959 shares of company stock valued at $109,672,752 in the last ninety days. Insiders own 0.11% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eli Lilly And Co (LLY) Issues FY19 Earnings Guidance” was first published by Rockland Register and is owned by of Rockland Register. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://rocklandregister.com/2019/05/15/eli-lilly-and-co-lly-updates-fy19-earnings-guidance.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: What is the Book Value of a Share?

Earnings History and Estimates for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.